Kymera Therapeutics (KYMR) Misses Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Join SI Premium – FREE
Kymera Therapeutics (NASDAQ: KYMR) reported Q4 EPS of ($0.97), $0.18 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $2.87 million versus the consensus estimate of $15 million.
For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Reiterates Sector Perform Rating on Bausch Health Companies (BHC)
- Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
- Levi (LEVI) Tops Q3 EPS by 12c; raises guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
